Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2021

Open Access 01-12-2021 | Correction

Correction to: Novel and emerging therapies for B cell lymphoma

Authors: Sabarish Ayyappan, Kimi Maddocks

Published in: Journal of Hematology & Oncology | Issue 1/2021

Login to get access

Excerpt

There is an error in Table 1 of the original article. Lisocabtagene maraleucel (liso-cel) is administered as a flat dose of 1 × 108 CAR T cells, regardless of a patient’s weight. The table incorrectly lists the dose as 1 × 108 cells/kg. …
Literature
1.
Metadata
Title
Correction to: Novel and emerging therapies for B cell lymphoma
Authors
Sabarish Ayyappan
Kimi Maddocks
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-020-01022-w

Other articles of this Issue 1/2021

Journal of Hematology & Oncology 1/2021 Go to the issue

Review

The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers

Research

Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma

Research

Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism

Review

Targeting hypoxic tumor microenvironment in pancreatic cancer

Letter to the Editor

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin

Letter to the Editor

SELP Asp603Asn and severe thrombosis in COVID-19 males
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits